Januvia 50 mg - 28 F.C. Tablet

Antidiabetic agent belongs to Dipeptidyl Peptidase 4 (DPP-4) Inhibitors used in the treatment of type 2 diabetes mellitus.

Administer without regard to meals.

-Arthralgia may occur within 1 day to years after treatment initiation, bullous pemphigoid, Stevens-Johnson syndrome or toxic epidermal necrolysis, anaphylaxis and angioedema, acute pancreatitis, chronic pancreatitis and pancreatic cancer especially in the patients with a prior history of pancreatitis or patients with acute pancreatitis due to any cause. -Hypoglycemia, nasopharyngitis, constipation, oral mucosa ulcer, stomatitis, vomiting, increased liver enzymes, anaphylaxis, angioedema, headache, myalgia, acute renal failure.

-Should not be given to patients suffering from hypersensitivity to sitagliptin. -Use with caution in patients with moderate to severe renal dysfunction and end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis; dosing adjustment required. -Not indicated for use in patients with type 1 diabetes. -Sitagliptin has not been studied exclusively in the elderly (>65 years). -In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Store at room temperature.

-Alpha-Lipoic Acid: May enhance the hypoglycemic effect of antidiabetic agents. -Angiotensin-Converting Enzyme Inhibitors: Dipeptidyl Peptidase-IV Inhibitors may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. -Digoxin: sitagliptin may increase the serum concentration of digoxin. -Direct acting antiviral agents (HCV): May enhance the hypoglycemic effect of antidiabetic agents. -Hypoglycemia-associated agents: Antidiabetic agents may enhance the hypoglycemic effect of hypoglycemia-associated agents. -Insulins: Dipeptidyl Peptidase-IV Inhibitors may enhance the hypoglycemic effect of insulins. -Monoamine oxidase inhibitors: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Quinolones: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Salicylates: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Sulfonylureas: Dipeptidyl Peptidase-IV Inhibitors may enhance the hypoglycemic effect of Sulfonylureas. -Thiazide diuretics: May diminish the therapeutic effect of antidiabetic agents.

-Information related to the use of sitagliptin in pregnancy is limited. Agents other than sitagliptin are currently recommended to treat diabetes mellitus in pregnancy. -It is not known if sitagliptin is present in breast milk, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. -Ask your physician before taking any medication during pregnancy or lactation.

MSD